Equillium Beheer

Beheer criteriumcontroles 3/4

De CEO Equillium is Bruce Steel, benoemd in Jan2006, heeft een ambtstermijn van 18.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.35M, bestaande uit 33.8% salaris en 66.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 10.48% van de aandelen van het bedrijf, ter waarde $ 2.75M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.7 jaar en 6.2 jaar.

Belangrijke informatie

Bruce Steel

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	33.8%
Dienstverband CEO	18.8yrs
Eigendom CEO	10.5%
Management gemiddelde ambtstermijn	6.7yrs
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

Nov 16

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Aug 12

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

May 03

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Mar 26

Equillium GAAP EPS of -$0.41 in-line

Aug 15

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Oct 08

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Mar 09

Equillium prices $30M registered direct offering

Feb 04

Equillium (EQ) Investor Presentation - Slideshow

Dec 04

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Nov 24

FDA gives green signal to Equillium's late-stage COVID-19 trial

Oct 30

Analyse CEO-vergoeding

Hoe is Bruce Steel's beloning veranderd ten opzichte van Equillium's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$1m	US$455k	-US$13m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$455k	-US$62m
Sep 30 2022	n/a	n/a	-US$76m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$2m	US$440k	-US$39m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$31m
Dec 31 2020	US$782k	US$198k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$28m
Mar 31 2020	n/a	n/a	-US$27m
Dec 31 2019	US$1m	US$396k	-US$26m
Sep 30 2019	n/a	n/a	-US$23m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$452k	US$219k	-US$13m

Compensatie versus markt: De totale vergoeding ($USD 1.35M ) Bruce } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Bruce is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bruce Steel (58 yo)

18.8yrs

Tenure

US$1,348,215

Compensatie

Mr. Bruce D. Steel, CFA has been Chief Executive Officer of Equillium, Inc. since January 1, 2020. He has been a Managing Director at BioMed Ventures LP since September 2010. Mr. Steel serves as President...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Bradbury	Executive Chairman	7.7yrs	US$267.30k	5.29% $ 1.4m
Bruce Steel	Co-Founder	18.8yrs	US$1.35m	10.48% $ 2.7m
Christine Zedelmayer	Senior VP & COO	6.8yrs	US$785.51k	0.38% $ 100.1k
Stephen Connelly	Chief Scientific Officer & Director	6.8yrs	US$827.25k	2.8% $ 734.8k
Jason Keyes	Chief Financial Officer	6.7yrs	geen gegevens	0.34% $ 90.0k
Penny Tom	Senior VP of Finance & Principal Accounting Officer	no data	geen gegevens	0.018% $ 4.8k
Michael Moore	Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Matthew Ritter	Senior Vice President of Corporate Development	4.5yrs	geen gegevens	geen gegevens
Joel Rothman	Chief Development Officer	4.9yrs	geen gegevens	0.16% $ 43.0k

6.7yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EQ is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Bradbury	Executive Chairman	7.7yrs	US$267.30k	5.29% $ 1.4m
Bruce Steel	Co-Founder	7.7yrs	US$1.35m	10.48% $ 2.7m
Stephen Connelly	Chief Scientific Officer & Director	7.7yrs	US$827.25k	2.8% $ 734.8k
Martha Demski	Independent Director	6.2yrs	US$98.77k	0.067% $ 17.6k
Bala Manian	Independent Director	7.5yrs	US$101.79k	0.067% $ 17.6k
Thomas Daniel	Member of Scientific & Clinical Advisory Board	5.5yrs	geen gegevens	geen gegevens
Mark Pruzanski	Independent Director	6.2yrs	US$83.77k	0.067% $ 17.6k
Vijay Kuchroo	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Barbara Troupin	Independent Director	2.8yrs	US$65.25k	0% $ 0
Charles McDermott	Independent Director	6.2yrs	US$60.69k	0.067% $ 17.6k
Fred Ramsdell	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Yu Xu	Independent Director	3.8yrs	US$74.86k	0% $ 0

6.2yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Equillium Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Insufficient new directors

Insufficient new directors

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Senior VP & COO notifies of intention to sell stock

Recent updates

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

New major risk - Financial position

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Price target decreased by 49% to US$3.33

Consensus revenue estimates fall by 27%

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop

Consensus revenue estimates increase by 35%

Forecast to breakeven in 2024

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Financial position

New major risk - Share price stability

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Price target increased by 9.5% to US$6.75

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

Consensus EPS estimates fall by 188%

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

New major risk - Share price stability

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

New minor risk - Share price stability

Price target decreased by 10% to US$6.17

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Consensus revenue estimates increase by 187%

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Consensus revenue estimates increase by 17%

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Price target decreased to US$12.00

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Price target decreased to US$12.00

Price target increased to US$14.00

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Equillium GAAP EPS of -$0.41 in-line

Insufficient new directors

Price target increased to US$13.75

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Price target decreased to US$12.50

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

Senior VP & COO notifies of intention to sell stock

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Chief Scientific Officer & Director exercised options and sold US$138k worth of stock

Price target decreased to US$13.75

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association